Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

July 27, 2022

Study Completion Date

July 27, 2022

Conditions
Dry Eye DiseaseKerato Conjunctivitis Sicca
Interventions
DRUG

Pilocarpine Ophthalmic Topical Cream, Dose 1

Pilocarpine Ophthalmic Topical Cream, Dose 1

DRUG

Pilocarpine Ophthalmic Topical Cream, Dose 2

Pilocarpine Ophthalmic Topical Cream, Dose 2

DRUG

Pilocarpine Ophthalmic Topical Cream, Dose 3

Pilocarpine Ophthalmic Topical Cream, Dose 3

DRUG

Placebo Ophthalmic Topical Cream

Placebo Ophthalmic Topical Cream

Trial Locations (19)

14618

Glaukos Investigator, Rochester

16066

Glaukos Investigator, Cranberry Township

24502

Glaukos Investigator, Lynchburg

30076

Glaukos Investigator, Roswell

33901

Glaukos Investigator, Fort Myers

37215

Glaukos Investigator, Nashville

38119

Glaukos Investigator, Memphis

63131

Glaukos Investigator, St Louis

77025

Glaukos Investigator, Houston

78229

Glaukos Investigator, San Antonio

81501

Glaukos Investigator, Grand Junction

85224

Glaukos Investigator, Chandler

85351

Glaukos Investigator, Sun City

89052

Glaukos Investigator, Henderson

91204

Glaukos Investigator, Glendale

91345

Glaukos Investigator, Mission Hills

92663

Glaukos Investigator, Newport Beach

94954

Glaukos Investigator, Petaluma

95670

Glaukos Investigator, Rancho Cordova

Sponsors
All Listed Sponsors
lead

Glaukos Corporation

INDUSTRY

NCT05119920 - Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease | Biotech Hunter | Biotech Hunter